Targeting Histone Deacetylases in Cancer (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 198
Special Issue Editor
Interests: cancerogenesis; epigenetics; histone deacetylases; miRNA; gastrointestinal tract; hepatopancreatic cancer; epithelial-mesen-chymal-transition; targeted therapy; tumor regression; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the previously successful “Targeting Histone Deacetylases in Cancer” (https://www.mdpi.com/journal/cancers/special_issues/histone_deacetylases).
Overall, the processes of human cancer initiation, progression, and metastasis are essentially linked to pathologic epigenetic deregulations via DNA methylation and/or histone modification.
The modification of histones—such as histone de-/acetylation—represents a major epigenetic regulatory mechanism and plays a significant role in human carcinogenesis. Histone deacetylation processes are regulated by a group of enzymes called histone deacetylases (HDACs), which can be categorized into four classes. Heterogeneous up- and downregulation of HDACs has been reported in several human cancer types, making these regulative enzymes a very interesting new potential therapeutic target. HDACs also regulate the acetylation status of a variety of other nonhistone substrates, including key tumor oncogenetic and suppressive genes, as well as associated proteins.
To date, most chemically developed histone deacetylase inhibitors (HDACis) have not been HDAC class- or HDAC class member-specific. Therefore, the development of new, highly selective histone deacetylase inhibitors is a challenging and very promising scientific field. Additionally, treatment strategies combining HDACis with approved anticancer drugs could essentially improve the therapeutic success rate through the inhibition of the tumor resistance mechanism or re-induction of primarily epigenetic silenced and consecutive possible druggable proteins in future.
This Special Issue calls again for researchers to contribute original research papers and reviews focused on targeting histone deacetylases in human cancer and their therapies in order to provide both an up-to-date overview of the current knowledge as well as a platform via which to present novel scientific results addressing the promising and increasingly cited research field of epigenetics in cancer therapy.
Dr. Daniel Neureiter
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetic dependent carcinogenesis
- histone modulation
- histone deacetylases (HDACs)
- HDAC profiling in human cancer
- HDAC inhibitor (HDACi) development and mechanism in human cancer
- combinatory treatment strategies of HDACis
- HDACis inhibition of cancer therapy resistance mechanism
- HDACis induction of epigenetic silenced druggable proteins
- clinical role of HDACis in human cancer
